Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
In recent transactions involving Senti Biosciences, Inc. (NASDAQ:SNTI), a small-cap biotech company with a market capitalization of $20 million, CEO Timothy Lu sold shares of the company, according to a filing with the Securities and Exchange Commission. According to InvestingPro data, the stock has shown significant volatility, with a beta of 2.47, making these insider transactions particularly noteworthy. On February 4 and February 6, Lu sold a total of 4,467 shares, with prices ranging from $4.07 to $4.36, resulting in a total sale value of $18,338.
The sales were part of a "sell-to-cover" policy, which automatically sells shares to cover tax withholding obligations related to the vesting of restricted stock units. These transactions reduced Lu’s direct ownership to 82,082 shares. Additionally, Lu holds 52,839 shares indirectly through the Luminen Trust, as noted in the filing. With SNTI’s current financial health score rated as ’WEAK’ by InvestingPro, investors should closely monitor insider activity patterns.
In other recent news, Senti Biosciences announced a change in its executive team as its Interim Chief Financial Officer, Yvonne Li, transitions to a consulting role. This move is part of the company’s ongoing efforts to manage its executive team and financial operations. Additionally, the company secured an additional $10 million investment through a private placement equity financing from Celadon Partners, raising the total capital to $47.6 million. The funds will be used for the development of Senti Bio’s SENTI-202 program and other corporate purposes.
In a separate development, Chardan Capital Markets raised the stock target for Senti Biosciences following positive trial data from the company’s phase I trial for SENTI-202, a treatment for hematologic malignancies. The firm maintained a Buy rating on the stock and increased the probability of success for SENTI-202.
Finally, Senti Biosciences announced the appointment of Fran Schulz to its Board of Directors and as chair of the Board’s Audit Committee. Schulz, having extensive experience in finance and life sciences, is expected to guide Senti Bio’s growth and innovation in its pipeline development. These are recent developments in the ongoing operations of Senti Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.